Welcome to the official website of Sichuan Purity Pharmaceutical Co., LTD.
Your location:Home>About>Our History
Deloitte China's Top 50 High Tech High Growth Companies in 2024.
Top 100 New Economy Enterprises in Sichuan Province in 2024.
Salmeterol and fluticasone dry powder inhalation approved.
2023 Deloitte China Rising Star.
Dexmedetomidine Hydrochloride Nasal Spray approved.
2024 Golden Panda Future Star.
2023 Sichuan Science and Technology Awards.
Formoterol Fumarate inhalation solution approved.
Levalbuterol Hydrochloride Inhalation Solution won the bid for the ninth batch of national centralized procurement.
Budesonide Nasal Spray approved.
2023 Deloitte Chengdu Rising Star.
Sichuan Province's specialized, refined, unique, and innovative small and medium-sized enterprises.
Innovation and Entrepreneurship Team of Tianfu Emei Plan.
Terbutaline Sulfate inhalation solution approved.
Levalbuterol Hydrochloride Inhalation Solution approved.
Terbutaline Sulfate Inhalation Solution won the bid for the seventh batch of national centralized procurement.
Budesonide Inhalation Suspension approved.
Albuterol Sulfate and Ipratropium Bromide Inhalation Solution approved.
Albuterol Sulfate Inhalation Solution won the bid for the fourth batch of national centralized procurement.
Ipratropium Bromide Inhalation Solution,Albuterol Sulfate and Ipratropium Bromide Inhalation Solution,Budesonide Inhalation Suspension won the bid for the fifth batch of national centralized procurement.
National high-tech enterprise.
Albuterol Sulfate Inhalation Solution approved.
Ipratropium Bromide Inhalation Solution approved.
Realize commercial production.
The production base was construced.
The first domestic new type of HFA-134a inhalation aerosol has passed the PK-BE test.
The construction of the production base has been initiated.
It obtained the clinical approval of the first inhalation aerosol.
The GMP pilot workshop was constructed.
The research and development center was constructed.
The company was established.